NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.

Tags: ovarian cancer

8/23/2018

Newsweek’s premature optimism about experimental ovarian cancer drug overlooks costs, harms and limitations of the evidence

3/26/2018

Significant conflicts of interest not disclosed in LA Times story on modified Pap tests

7/6/2017

Reuters turns unpublished pilot studies into news

10/14/2016

PARP inhibitors: STAT’s look at new ovarian cancer drugs should have established why we need more on the market

1 6/15/2016

Thorough story on underuse of new ovarian cancer tests needed a few more numbers

10/12/2015

Kids after cancer treatment? HealthDay breaks down evidence on ovarian transplant procedure

8/27/2015

WSJ fills holes left by incomplete news release on beta-blockers and ovarian cancer

2 3/28/2015

Experts Back Angelina Jolie Pitt in Choices for Cancer Prevention

2/9/2012

New treatment deep freezes ovarian tumors

11/8/2011

Study: Vaccine for Breast, Ovarian Cancer Has Potential